<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02908880</url>
  </required_header>
  <id_info>
    <org_study_id>PSD-109</org_study_id>
    <nct_id>NCT02908880</nct_id>
  </id_info>
  <brief_title>MANTA Percutaneous Vascular Closure Device - The SAFE MANTA Study</brief_title>
  <acronym>SAFE_MANTA</acronym>
  <official_title>Pivotal Clinical Study to EvaluAte the SaFety and Effectiveness of MANTA Vascular Closure Device</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Essential Medical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Essential Medical, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Research study which tests the safety and effectiveness of a new vascular closure device to
      close the femoral access puncture that is created in patients who require this form of access
      in order to perform the planned procedure. The MANTA device is expected to seal the femoral
      access puncture in less than 1 minute. This may result in less blood loss and a shorter time
      to walking compared to alternative closure means. Use of the MANTA device in this study is
      experimental. All other parts of the procedure involve standard medical care.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The MANTA device is a VCD intended for use in catheterization laboratories following
      percutaneous cardiac or peripheral procedures that use the retrograde common femoral artery
      access route for large bore (10‐18F ID) interventional devices. The function of MANTA is to
      percutaneously close the puncture in the artery wall (arteriotomy) through which the
      catheters were inserted for the procedure.

      The study is being conducted to demonstrate the safety and effectiveness of MANTA in
      achieving hemostasis in femoral arterial access sites in subjects undergoing percutaneous
      transcatheter interventional procedures using a large-bore procedure sheath.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Actual">December 2017</completion_date>
  <primary_completion_date type="Actual">October 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Hemostasis</measure>
    <time_frame>During access site closure, usually within an hour of starting the procedure.</time_frame>
    <description>The elapsed time between withdrawal of MANTA sheath/device from artery and first observed and confirmed arterial hemostasis (no or minimal subcutaneous oozing and the absence of expanding or developing hematoma).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Patients With Major Complications, Within 30 Days of Procedure</measure>
    <time_frame>Up to 30 days after procedure</time_frame>
    <description>IDE Protocol-Defined Major Complications analyzed on a per-patient basis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Technical Success</measure>
    <time_frame>Within 6 hours after deployment of the MANTA device</time_frame>
    <description>Percutaneous vascular closure obtained with the MANTA device without the use of unplanned endovascular or surgical intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With VARC-2 Major Vascular Complications, Adapted From the VARC-2 Criteria, Within 30 Days of Procedure</measure>
    <time_frame>Up to 30 days after procedure</time_frame>
    <description>Incidence of VARC-2 Major Vascular Complications, analyzed on a per-patient basis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Minor Complications, Within 30 Days of Procedure</measure>
    <time_frame>Up to 30 days after procedure</time_frame>
    <description>Incidence of IDE Protocol-defined Minor Complications, analyzed on a per-patient analysis</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">263</enrollment>
  <condition>Femoral Arteriotomy Closure</condition>
  <arm_group>
    <arm_group_label>MANTA vascular closure device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open label, single arm study using the MANTA device, developed by Essential Medical, Inc. MANTA is a vascular closure device (VCD) intended for use in catheterization laboratories following percutaneous cardiac or peripheral procedures that use the retrograde common femoral artery access route for large bore (10-18F) interventional devices.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MANTA vascular closure device</intervention_name>
    <description>The appropriate size of MANTA closure device will be selected and used for the closure of femoral arterial access sites following the use of 10-14F devices or sheaths or the use of 15-18F devices or sheaths.</description>
    <arm_group_label>MANTA vascular closure device</arm_group_label>
    <other_name>MANTA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Candidate for elective or planned (i.e., not emergent or urgent) percutaneous
             transcatheter interventional procedure via a 10-18F size retrograde common femoral
             artery approach (i.e., transcatheter aortic valve implantation [TAVI], endovascular
             aneurysm repair [EVAR], Impella® use)

          2. Vessel size would allow for access for the MANTA device as determined by baseline CTA:
             minimum vessel diameter 5mm for the 14F MANTA and 6mm for the 18F MANTA

          3. Eligible for sheath removal in the catheterization lab

          4. Age ≥21 years

          5. Understand and sign the study specific written informed consent form

          6. Able and willing to fulfill the follow-up requirements

          7. In the investigator's opinion, patient is suitable for the MANTA vascular closure
             device, conventional hemostasis techniques and participation in an investigational
             trial

        Exclusion Criteria:

          1. Known to be pregnant or lactating

          2. Immunocompromised or with pre-existing autoimmune disease

          3. Systemic infection or a local infection at or near the access site

          4. Significant anemia (hemoglobin &lt;10 g/DL, hematocrit &lt;30%)

          5. Morbidly obese or cachectic (BMI &gt;40 kg/m2 or &lt;20 kg/m2)

          6. Known bleeding disorder including thrombocytopenia (platelet count &lt;100,000 cells/UL),
             thrombasthenia, hemophilia, or von Willebrand disease

          7. Allergy to bovine materials or any other device material, including collagen and/or
             collagen products, polyglycolic or polylactic acid, stainless steel or nickel

          8. Femoral artery puncture in target groin within the prior 14 days

          9. Previous iliofemoral intervention in region of access site, including but not limited
             to prior atherectomy, stenting, surgical or grafting procedures in the access area

         10. Patients who have undergone use of an intra-aortic balloon pump through the arterial
             access site within 30 days prior to the baseline evaluation

         11. Patients who are not mobile and are confined to a wheelchair or bed

         12. NYHA class IV heart failure

         13. Patients who have already participated in the IDE study

         14. Currently participating in another clinical trial of an unapproved investigational
             device or drug that has not concluded the follow-up period

         15. Patient cannot adhere to or complete the investigational protocol for any reason
             including but not limited to geographical residence, psychiatric condition or life
             threatening disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Wood, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Paul's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Zvonimir Krajcer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Luke's Episcopal</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>San Diego VA Medical Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92161</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington Hospital Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evanston Hospital</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent Heart Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46290</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke Hospital (Mid America Heart)</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Temple University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lankenau Heart Group</name>
      <address>
        <city>Wynnewood</city>
        <state>Pennsylvania</state>
        <zip>19096</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Avera Heart Hospital</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wellmont Holston Valley Hospital</name>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <zip>37660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Houston Methodist</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's Hospital - Texas Heart</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Heart Hospital Baylor Plano</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CAMC Memorial Hospital</name>
      <address>
        <city>Charleston</city>
        <state>West Virginia</state>
        <zip>25304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Paul's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 9, 2016</study_first_submitted>
  <study_first_submitted_qc>September 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2016</study_first_posted>
  <results_first_submitted>April 12, 2019</results_first_submitted>
  <results_first_submitted_qc>April 12, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">May 7, 2019</results_first_posted>
  <disposition_first_submitted>October 17, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>October 19, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">October 23, 2018</disposition_first_posted>
  <last_update_submitted>September 24, 2019</last_update_submitted>
  <last_update_submitted_qc>September 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MANTA</keyword>
  <keyword>Arterial Closure Device</keyword>
  <keyword>Large Bore Closure Device</keyword>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The data obtained will be used, without mentioning Subject PHI, to assess the results of the research, and the data could be used in the future with regard to this study or other studies. The data can be passed on to the health authorities for the purposes of registering the medical device.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 2, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/80/NCT02908880/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 6, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/80/NCT02908880/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>MANTA Vascular Closure Device</title>
          <description>Open label, single arm study using the MANTA device, developed by Essential Medical, Inc.. MANTA is a vascular closure device (VCD) intended for use in catheterization laboratories following percutaneous cardiac or peripheral procedures that use the retrograde common femoral artery access route for large bore (10-18F) interventional devices.
MANTA vascular closure device: The appropriate size of MANTA closure device will be selected and used to for the closure of femoral arterial access sites following the use of 10-14F devices or sheaths or the use of 15-18F devices or sheaths.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="263">Subjects within the Primary Analysis Cohort that received the MANTA Device</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="236">Subjects within the Primary Analysis Cohort that completed all follow-up time points.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Explantation of the device</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>MANTA Vascular Closure Device</title>
          <description>Open label, single arm study using the MANTA device, developed by Essential Medical, Inc.. MANTA is a vascular closure device (VCD) intended for use in catheterization laboratories following percutaneous cardiac or peripheral procedures that use the retrograde common femoral artery access route for large bore (10-18F) interventional devices.
MANTA vascular closure device: The appropriate size of MANTA closure device will be selected and used to for the closure of femoral arterial access sites following the use of 10-14F devices or sheaths or the use of 15-18F devices or sheaths.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="263"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="254"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79.4" spread="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="93"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="170"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="247"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="247"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ankle Brachial Index (ABI)</title>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.1" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.6" spread="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Minimum Target Vessel Diameter</title>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.9" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Creatinine</title>
          <units>umol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="97.1" spread="27.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hematocrit</title>
          <units>L/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.39" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hemoglobin</title>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.1" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Platelets</title>
          <units>10^9/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="199.1" spread="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to Hemostasis</title>
        <description>The elapsed time between withdrawal of MANTA sheath/device from artery and first observed and confirmed arterial hemostasis (no or minimal subcutaneous oozing and the absence of expanding or developing hematoma).</description>
        <time_frame>During access site closure, usually within an hour of starting the procedure.</time_frame>
        <population>Primary Analysis Cohort</population>
        <group_list>
          <group group_id="O1">
            <title>MANTA Vascular Closure Device</title>
            <description>Open label, single arm study using the MANTA device, developed by Essential Medical, Inc.. MANTA is a vascular closure device (VCD) intended for use in catheterization laboratories following percutaneous cardiac or peripheral procedures that use the retrograde common femoral artery access route for large bore (10-18F) interventional devices.
MANTA vascular closure device: The appropriate size of MANTA closure device will be selected and used to for the closure of femoral arterial access sites following the use of 10-14F devices or sheaths or the use of 15-18F devices or sheaths.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Hemostasis</title>
          <description>The elapsed time between withdrawal of MANTA sheath/device from artery and first observed and confirmed arterial hemostasis (no or minimal subcutaneous oozing and the absence of expanding or developing hematoma).</description>
          <population>Primary Analysis Cohort</population>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="263"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.4" spread="157.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Major Complications, Within 30 Days of Procedure</title>
        <description>IDE Protocol-Defined Major Complications analyzed on a per-patient basis</description>
        <time_frame>Up to 30 days after procedure</time_frame>
        <population>Primary Analysis Cohort</population>
        <group_list>
          <group group_id="O1">
            <title>MANTA Vascular Closure Device</title>
            <description>Open label, single arm study using the MANTA device, developed by Essential Medical, Inc.. MANTA is a vascular closure device (VCD) intended for use in catheterization laboratories following percutaneous cardiac or peripheral procedures that use the retrograde common femoral artery access route for large bore (10-18F) interventional devices.
MANTA vascular closure device: The appropriate size of MANTA closure device will be selected and used to for the closure of femoral arterial access sites following the use of 10-14F devices or sheaths or the use of 15-18F devices or sheaths.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Major Complications, Within 30 Days of Procedure</title>
          <description>IDE Protocol-Defined Major Complications analyzed on a per-patient basis</description>
          <population>Primary Analysis Cohort</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="263"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Technical Success</title>
        <description>Percutaneous vascular closure obtained with the MANTA device without the use of unplanned endovascular or surgical intervention</description>
        <time_frame>Within 6 hours after deployment of the MANTA device</time_frame>
        <population>Primary Analysis Cohort</population>
        <group_list>
          <group group_id="O1">
            <title>MANTA Vascular Closure Device</title>
            <description>Open label, single arm study using the MANTA device, developed by Essential Medical, Inc.. MANTA is a vascular closure device (VCD) intended for use in catheterization laboratories following percutaneous cardiac or peripheral procedures that use the retrograde common femoral artery access route for large bore (10-18F) interventional devices.
MANTA vascular closure device: The appropriate size of MANTA closure device will be selected and used to for the closure of femoral arterial access sites following the use of 10-14F devices or sheaths or the use of 15-18F devices or sheaths.</description>
          </group>
        </group_list>
        <measure>
          <title>Technical Success</title>
          <description>Percutaneous vascular closure obtained with the MANTA device without the use of unplanned endovascular or surgical intervention</description>
          <population>Primary Analysis Cohort</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="263"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="257"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With VARC-2 Major Vascular Complications, Adapted From the VARC-2 Criteria, Within 30 Days of Procedure</title>
        <description>Incidence of VARC-2 Major Vascular Complications, analyzed on a per-patient basis</description>
        <time_frame>Up to 30 days after procedure</time_frame>
        <population>Primary Analysis Cohort</population>
        <group_list>
          <group group_id="O1">
            <title>MANTA Vascular Closure Device</title>
            <description>Open label, single arm study using the MANTA device, developed by Essential Medical, Inc.. MANTA is a vascular closure device (VCD) intended for use in catheterization laboratories following percutaneous cardiac or peripheral procedures that use the retrograde common femoral artery access route for large bore (10-18F) interventional devices.
MANTA vascular closure device: The appropriate size of MANTA closure device will be selected and used to for the closure of femoral arterial access sites following the use of 10-14F devices or sheaths or the use of 15-18F devices or sheaths.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With VARC-2 Major Vascular Complications, Adapted From the VARC-2 Criteria, Within 30 Days of Procedure</title>
          <description>Incidence of VARC-2 Major Vascular Complications, analyzed on a per-patient basis</description>
          <population>Primary Analysis Cohort</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="263"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Minor Complications, Within 30 Days of Procedure</title>
        <description>Incidence of IDE Protocol-defined Minor Complications, analyzed on a per-patient analysis</description>
        <time_frame>Up to 30 days after procedure</time_frame>
        <population>Primary Analysis Cohort</population>
        <group_list>
          <group group_id="O1">
            <title>MANTA Vascular Closure Device</title>
            <description>Open label, single arm study using the MANTA device, developed by Essential Medical, Inc.. MANTA is a vascular closure device (VCD) intended for use in catheterization laboratories following percutaneous cardiac or peripheral procedures that use the retrograde common femoral artery access route for large bore (10-18F) interventional devices.
MANTA vascular closure device: The appropriate size of MANTA closure device will be selected and used to for the closure of femoral arterial access sites following the use of 10-14F devices or sheaths or the use of 15-18F devices or sheaths.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Minor Complications, Within 30 Days of Procedure</title>
          <description>Incidence of IDE Protocol-defined Minor Complications, analyzed on a per-patient analysis</description>
          <population>Primary Analysis Cohort</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="263"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Approximately 60 days after deployment of the MANTA device</time_frame>
      <group_list>
        <group group_id="E1">
          <title>MANTA Vascular Closure Device</title>
          <description>Open label, single arm study using the MANTA device, developed by Essential Medical, Inc.. MANTA is a vascular closure device (VCD) intended for use in catheterization laboratories following percutaneous cardiac or peripheral procedures that use the retrograde common femoral artery access route for large bore (10-18F) interventional devices.
MANTA vascular closure device: The appropriate size of MANTA closure device will be selected and used to for the closure of femoral arterial access sites following the use of 10-14F devices or sheaths or the use of 15-18F devices or sheaths.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="70" subjects_at_risk="263"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Mild leukocytosis of non study leg</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Complete Heart Block</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Heart Block</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Congestive Heart Failure Exacerbation</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Cardiogenic Shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Left Bundle Branch Block</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Thrombus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Sinus arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>AV Nodal Conduction Disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Atrial Flutter</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Arrhythmia not otherwise noted</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Acute Cardiac Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Severe Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Retroperitoneal bleed</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Ischemic Bowel</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Abnormal Gait</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Septic Shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Systemic Infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="263"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Access site bleeding-arterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Valve thrombosis or patient prothesis mismatch</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Pseudoaneurysm</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Access site Occlusion</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Multiple falls with prolonged immobilization</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Decrease in Ejection Fraction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Local infection at location other than femoral access sites</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Acute gout on left knee</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>PPM pocket hematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Left arm and shoulder pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Recurrent lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Vaso-vagal Event</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Acute Aphasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Stroke/cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Intraparenchymal Hemorrhage in left frontal lobe</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Hemorrhage within horizontal sylvian fissure on left and intraventricular hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Acute Metabolic Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Transient ischemic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Decreased cardiac functional status</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute urinary retention post TAVI</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Acute Kidney Injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Urinary Retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Renal Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COPD Exacerbation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Acute Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Shortness of Breath</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Right lower lobe pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Respiratory Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Pulmonary Edema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Femoral artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Retrograde dissection originating at puncture site</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Distal External Iliact Artery Stenosis &gt;50%</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Limb ischemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Hypovolemic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>NSTEMI</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Arterial embolism to limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Type A Aortic dissection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Left Arm Hematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="71" subjects_at_risk="263"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Left Bundle Branch Block</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="263"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Access site bleeding-oozing</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Hematoma</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="263"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Typical language included: Research Institution and Principal Investigator agree that they shall not, without the Sponsor’s prior written consent, independently Publish any results of or information about the activities conducted until the multi-center publication is released. If a multi-center manuscript is not submitted for publication within one (1) year after completion of the multi-center Study, Research Institution and Principal Investigator shall have the right to Publish results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sam Nardone</name_or_title>
      <organization>Essential Medical, Inc.</organization>
      <phone>6105571009</phone>
      <email>sam@essmedclosure.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

